CHAPTER 1 - MARKET SUMMARY
Market Overview
The India Molecular Diagnostics Market operates through the sale of assay kits, reagents, instruments, software and testing services to hospital laboratories, diagnostic chains, public-health programs and research institutions. Demand is structurally supported by approximately 1.57 million projected new cancer cases in 2025, alongside persistent tuberculosis, hepatitis, HIV and antimicrobial-resistance testing requirements.
Commercial capacity is concentrated in Delhi NCR, Maharashtra, Karnataka, Telangana, Tamil Nadu and Gujarat, where tertiary hospitals, reference laboratories, biotechnology clusters and clinical-research centers support high-complexity testing. National TB infrastructure expanded substantially, with 4,720 molecular diagnostic laboratories established over eight years and district-level availability of rapid molecular testing, improving instrument utilization beyond major metros.
Market Value
USD 1,130 million
2025
Dominant Region
South India
2025
Dominant Segment
Technology
fastest growing, 2026-2031
Total Number of Players
65
Future Outlook
The India Molecular Diagnostics Market is projected to expand from USD 1,130 million in 2025 to USD 1,833 million by 2031, representing an 8.40% forecast CAGR. This compares with a 7.70% historical CAGR during 2020-2025, when the market experienced pandemic-related volume volatility followed by normalization and renewed adoption in oncology, tuberculosis, transplant testing and genetic diagnostics. The next growth phase will be less dependent on respiratory testing and increasingly supported by multiplex assays, decentralized PCR, next-generation sequencing and recurring reagent consumption across public and private laboratories.
Revenue growth will be supported by rising test penetration and gradual movement toward higher-value assays rather than instrument placements alone. Test-equivalent volume is projected to increase from approximately 52 million in 2025 to 83 million by 2031. Reagents and assay kits will remain the largest recurring profit pool, while digital PCR, syndromic testing, oncology panels and sequencing will record faster adoption. Downside risks include reimbursement pressure, imported component exposure, quality variability and uneven specialist availability. Upside depends on domestic manufacturing, public procurement, integrated laboratory networks and the commercialization of population-specific genomic insights.
8.40%
Forecast CAGR
$1,833 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2026-2031
Historical CAGR
7.70%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
CAGR, reagent margins, recurring revenue, regulatory risk, localization
Corporates
assay portfolio, platform utilization, pricing, distribution, partnerships, expansion
Government
disease surveillance, procurement, affordability, localization, laboratory quality, access
Operators
turnaround time, throughput, quality controls, staffing, maintenance, referrals
Financial institutions
equipment finance, cash flows, tender exposure, scalability, covenants
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
The market's historical peak growth occurred in 2021, when molecular testing demand expanded by 21.8% and test-equivalent volume increased by 42.5%. The subsequent 7.4% value contraction in 2022 represented normalization rather than structural decline. From 2023 onward, demand shifted toward tuberculosis, viral-load monitoring, oncology profiling, HPV screening and inherited-disease testing. Reagent consumption recovered faster than instrument placements, while centralized laboratories retained complex NGS workflows and portable PCR platforms expanded district-level testing. The period closed with an estimated 52 million test equivalents in 2025.
Forecast Market Outlook (2026-2031)
Forecast growth is expected to remain comparatively stable at 8.40% annually, with market value reaching USD 1,833 million by 2031. The growth mix will shift toward recurring assays, multiplex panels and higher-value molecular interpretation services. Test-equivalent volume is projected to reach 83 million, implying approximately 8.1% annual volume expansion from 2025. Digital PCR and NGS will grow faster than conventional platforms, although real-time PCR will retain the largest installed base. Local manufacturing, reagent-rental contracts and public-health procurement will improve access, while premium oncology and genetic assays sustain value growth.
CHAPTER 5 - Market Data
Market Breakdown
The India Molecular Diagnostics Market is transitioning from pandemic-led episodic testing toward diversified recurring demand. For CEOs and investors, the primary value-creation levers are assay volume, installed testing capacity and the localization of kits, reagents and instrument components.
Year | Market Size (USD Mn) | YoY Growth (%) | Test-Equivalent Volume (Mn) | Molecular Testing Sites | Locally Supplied Kit Share (%) | Period |
|---|---|---|---|---|---|---|
| 2020 | $780 Mn | +- | 40 | 2,600 | Forecast | |
| 2021 | $950 Mn | +21.8% | 57 | 3,164 | Forecast | |
| 2022 | $880 Mn | +-7.4% | 44 | 4,720 | Forecast | |
| 2023 | $940 Mn | +6.8% | 46 | 5,050 | Forecast | |
| 2024 | $1,055 Mn | +12.2% | 49 | 5,400 | Forecast | |
| 2025 | $1,130 Mn | +7.1% | 52 | 5,800 | Forecast | |
| 2026 | $1,225 Mn | +8.4% | 56 | 6,200 | Forecast | |
| 2027 | $1,328 Mn | +8.4% | 61 | 6,650 | Forecast | |
| 2028 | $1,439 Mn | +8.4% | 66 | 7,150 | Forecast | |
| 2029 | $1,560 Mn | +8.4% | 71 | 7,700 | Forecast | |
| 2030 | $1,691 Mn | +8.4% | 77 | 8,300 | Forecast | |
| 2031 | $1,833 Mn | +8.4% | 83 | 8,950 | Forecast |
Test-Equivalent Volume
52 million tests, 2025, India. Volume growth expands recurring reagent revenue and improves instrument utilization. India's TB program recorded approximately 3.53 million CBNAAT tests in 2019, demonstrating the scale achievable through programmatic procurement.
Molecular Testing Sites
5,800 sites, 2025, India. A broader site network lowers sample transport time and supports decentralized platforms. The government reported that 4,720 molecular diagnostic laboratories were established over eight years by 2022.
Locally Supplied Kit Share
42%, 2025, India. Localization improves tender competitiveness and reduces foreign-exchange exposure. Molbio reported FY2025 revenue of INR 1,020 crore with 22% year-over-year growth, illustrating the scale available to indigenous platform suppliers.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Product Type
Fastest Growing Segment
Technology
Product Type
Care Setting
End User
Disease Area
Channel
Technology
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Product Type
Reagents and assay kits dominate recurring revenue because each installed analyzer generates repeat consumption across disease panels. Instruments create the installed base, but recurring kits, controls and consumables carry higher replacement frequency. PCR and NAAT assays remain the largest Level-2 sub-segment, supported by infectious-disease programs, viral-load monitoring and hospital testing workflows.
Technology
Technology is the fastest-growing dimension as laboratories move from single-target testing toward multiplex PCR, digital PCR and sequencing. Next-Generation Sequencing is expected to be the fastest-growing Level-2 sub-segment, driven by oncology profiling, rare-disease diagnosis, prenatal testing and population genomics. Adoption will remain concentrated in high-throughput laboratories until sample preparation and interpretation costs decline.
CHAPTER 7 - Regional Analysis
Regional Analysis
India ranks third among selected Asian molecular-diagnostics markets by estimated 2025 value, behind Japan and China but ahead of South Korea and Indonesia. Its combination of high infectious-disease testing demand, expanding genomics infrastructure and lower operating costs supports a stronger growth profile than the more mature Japanese market.
Focus Country Ranking
3rd
Focus Country Market Size
USD 1.13 Bn
India CAGR (2026-2031)
8.40%
Focus Country Ranking
3rd
Focus Country Market Size
USD 1.13 Bn
India CAGR (2026-2031)
8.40%
Regional Analysis (Current Year)
Market Position
India ranks third within the selected peer group at USD 1.13 billion, with scale supported by national disease-control programs and a population exceeding 1.4 billion.
Growth Advantage
India's 8.40% CAGR exceeds Japan's 5.90% and China's 4.70%, reflecting lower testing penetration, rapid laboratory expansion and greater headroom for decentralized molecular platforms.
Competitive Strengths
India combines 10,000 accessible whole-genome samples, more than 4,700 added molecular laboratories and globally deployed indigenous PCR platforms, supporting research, localization and cost-efficient testing.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the India Molecular Diagnostics Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Expansion of Infectious-Disease Molecular Testing
- India operated 3,164 CBNAAT and Truenat machines (2021, India), enabling at least one rapid molecular diagnostic facility in each district and creating recurring cartridge demand for platform suppliers.
- Approximately 3.53 million CBNAAT tests (2019, India) were conducted through the TB program, demonstrating the commercial scale achievable when molecular assays are embedded in national diagnostic algorithms.
- India's TB prevalence survey found 33% of identified cases (2019-2021, India) were diagnosed exclusively through molecular testing, reinforcing the clinical value of sensitive NAAT technologies.
Rising Oncology and Genomics Demand
- Breast cancer accounted for a projected 232,832 cases (2025, India), creating a substantial testing pool for inherited risk, receptor profiling and therapy-selection assays.
- GenomeIndia made 10,000 whole-genome samples (2025, India) available to researchers, improving population-specific variant interpretation and supporting new genetic and pharmacogenomic assays.
- The national genomic repository included data from 9,772 samples and approximately 700 TB of FASTQ files (2025, India), expanding the evidence base for precision-medicine development.
Decentralization of Primary and Digital Healthcare
- The Free Diagnostics Service Initiative supports 14 tests at sub-centers and 63 tests at primary health centers (2025, India), establishing infrastructure that can refer higher-complexity molecular assays.
- India had created 79.75 crore ABHA IDs (June 2025, India), improving the potential for longitudinal diagnostic records and integrated laboratory reporting.
- Approximately 65.34 crore electronic health records (June 2025, India) had been linked across health portals, supporting digital ordering, result delivery and disease surveillance.
Market Challenges
Imported Instrument and Component Exposure
- Currency movement affects imported analyzers, enzymes, probes and specialty plastics, while market prices cannot always be adjusted immediately under multi-year public tenders (2025, India).
- Domestic manufacturing must meet the same licensing and quality requirements under Medical Devices Rules, 2017 (India), requiring investment in validation, stability studies and controlled manufacturing.
- Instrument downtime carries greater commercial impact outside metros because many district sites operate with limited backup capacity, despite more than 4,700 added molecular laboratories (2022, India).
Affordability and Reimbursement Constraints
- High-complexity oncology and sequencing panels frequently require out-of-pocket payment, limiting adoption beyond insured metropolitan patients despite 1.57 million projected cancer cases (2025, India).
- Government procurement concentrates purchasing power and can compress reagent prices, particularly where tenders specify cost-per-reportable-result contracts (2025, India) rather than instrument ownership.
- Private laboratories must balance affordability with specialist labor, quality controls and interpretation costs, while leading chains continue expanding advanced diagnostics into Tier 3 and Tier 4 cities (2024, India).
Quality, Skills and Data-Governance Gaps
- Sequencing and digital PCR require trained molecular pathologists, bioinformaticians and quality managers, creating bottlenecks outside established clusters despite 20-plus GenomeIndia institutions (2025, India).
- Variant interpretation can remain inconclusive without representative reference data; GenomeIndia included phenotypic data for 9,330 samples (2025, India), but broader clinical linkage is still required.
- Data-sharing must comply with Biotech-PRIDE and FeED protocols, adding governance requirements to research using approximately 700 TB of genomic files (2025, India).
Market Opportunities
Point-of-Care Molecular Platforms
- Reagent-rental and pay-per-test models can reduce upfront capital barriers, allowing platform owners to capture recurring revenue from more than 5,000 estimated testing sites (2025, India).
- Public-health agencies, district hospitals and regional distributors benefit from battery-operated platforms that reduce sample transport and support results near the patient within approximately two hours (platform benchmark).
- Opportunity realization requires service networks, quality-assurance programs and multiplex menus beyond TB, with Cepheid offering more than 20 tests registered in India (2024).
Indigenous Assays and Export Manufacturing
- Local manufacturers can monetize kits, instruments, service contracts and exports while reducing foreign-exchange exposure; Truenat had more than 10,000 devices across 80-plus countries (2025).
- Hospitals and public buyers benefit from locally supported platforms, while domestic suppliers gain faster field feedback and tender responsiveness across 4,720 added molecular laboratories (2022, India).
- Further scale requires globally acceptable clinical validation, stable reagent supply and automated manufacturing; India's bioeconomy reached USD 165.7 billion (2024, India).
Precision Oncology and Population Genomics
- Laboratories can capture higher revenue per test through tumor profiling, liquid biopsy and minimal residual disease testing across 1.57 million projected cancer cases (2025, India).
- Oncology hospitals, biopharma sponsors and patients benefit from treatment-selection assays, while clinical-trial networks gain access to population-specific genomic variants (2025, India).
- Commercialization requires payer evidence, standardized interpretation and clinician education; QIAGEN's India syndromic panel can analyze 15 pathogens in about 80 minutes (2024), illustrating the value of actionable multiplex results.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
The market combines multinational platform leaders with increasingly scaled indigenous suppliers. Competition centers on assay-menu breadth, installed-base utilization, tender pricing, service coverage, regulatory approvals and the ability to supply validated recurring reagents.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Roche Diagnostics India | - | Basel, Switzerland | 1896 | PCR, oncology assays, sequencing preparation and centralized laboratory systems |
Abbott India | - | Abbott Park, United States | 1888 | Infectious-disease molecular assays, viral-load testing and laboratory platforms |
Cepheid India | - | Sunnyvale, United States | 1996 | Cartridge-based PCR, tuberculosis testing and near-patient molecular diagnostics |
QIAGEN India | - | Venlo, Netherlands | 1984 | Sample preparation, syndromic panels, PCR, digital PCR and bioinformatics |
Thermo Fisher Scientific India | - | Waltham, United States | 2006 | PCR instruments, sequencing workflows, genetic analyzers and clinical research tools |
bioMérieux India | - | Marcy-l'Étoile, France | 1963 | Syndromic molecular testing and infectious-disease diagnostic systems |
Molbio Diagnostics | - | Goa, India | 2000 | Portable Truenat PCR platform and multi-disease point-of-care assays |
Mylab Discovery Solutions | - | Pune, India | 2016 | RT-PCR kits, automated molecular systems, infectious disease and HPV assays |
Bio-Rad Laboratories India | - | Hercules, United States | 1952 | Digital PCR, quality controls, amplification systems and laboratory reagents |
Hologic India | - | Marlborough, United States | 1985 | Women's health molecular diagnostics, HPV testing and automated assay systems |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Analysis Covered
Market Share Analysis:
Quantifies revenue concentration across multinational and indigenous platform suppliers nationally.
Cross Comparison Matrix:
Benchmarks assay breadth, installed systems, growth and reagent economics consistently.
SWOT Analysis:
Evaluates technology, distribution, regulatory and localization advantages across competitors systematically.
Pricing Strategy Analysis:
Compares reagent rental, tender, instrument and per-test pricing models.
Company Profiles:
Reviews market focus, platforms, headquarters and operational positioning of leaders.
CHAPTER 10 - REPORT TOC
Table of Contents
Market Assessment Phase
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Go-To-Market Strategy Phase
15 chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Survey Phase
8 chapters
Demand-side primary research conducted through structured interviews and online surveys with end users across priority metros and Tier 2/3 cities to capture consumption behavior, unmet needs, and purchase drivers.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Reviewed molecular diagnostics regulatory classifications
- Mapped national disease testing programs
- Analyzed company filings and portfolios
- Benchmarked assay pricing and utilization
Primary Research
- Interviewed laboratory medical directors
- Engaged molecular pathology department heads
- Consulted diagnostic procurement managers
- Surveyed molecular assay distributors
Validation and Triangulation
- Validated findings across 268 respondents
- Reconciled supplier and laboratory estimates
- Cross-checked test volumes and prices
- Applied disease-demand plausibility checks
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
- Indonesia Molecular Diagnostics Market Size, Share & Forecast, By Product Type, Technology, Disease Area & End User, 2026-2031
- Vietnam Molecular Diagnostics Market Size, Share & Forecast, By Product Type, Technology, Disease Area & End User, 2026-2031
- Thailand Molecular Diagnostics Market Size, Share & Forecast, By Product Type, Technology, Disease Area & End User, 2026-2031
- Malaysia Molecular Diagnostics Market Size, Share & Forecast, By Product Type, Technology, Disease Area & End User, 2026-2031
- Philippines Molecular Diagnostics Market Size, Share & Forecast, By Product Type, Technology, Disease Area & End User, 2026-2031
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- Philippines In-vitro Diagnostic Reagents Market
- Egypt Point-of-Care Testing Market
- Indonesia Genetic Testing Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Global Clinical Laboratory Services Market Size, Share & Forecast, By Service Type, Care Setting & End User, 2025-2032
- Mexico Molecular Laboratory Equipment Market
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals